Trieu Vuong's Form 4 filing
Oncotelic Therapeutics, Inc. (OTLC) · filed Jun 30, 2023
- Accession no.
- 0001493152-23-023015
- Filed
- Jun 30, 2023, 9:25 AM ET
- Trade date
- Jun 28-29, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $10.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Trieu VuongCIK 0001587074 | Director, Officer (CHAIRMAN AND CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2023 | Common Stock | PPurchaseAcquired | +425,000 | $0.021 | +$8,925 | 92,044,217 | Direct | |
| Jun 28, 2023 | Common Stock | PPurchaseAcquired | +75,000 | $0.026 | +$1,950 | 91,619,217 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
On June 28, 2023, Dr. Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.026. Further, on June 29, 2023, Dr. Trieu purchased 425,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.021.